NIH PAR · NCI · R01
PAR-25-079: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.
- NOFO number
- PAR-25-079
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Nov 6, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2027
PAR-25-079 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-079
NIH RePORTER lists 3 projects funded under PAR-25-079 in FY2022–FY2026, with $1.8M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$1.8M
Award dollars under PAR-25-079, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 2 | $1.8M |
Institutions with the most funding
- Vanderbilt University Medical Center$695K · 1 project
- UT Southwestern Medical Center$583K · 1 project
- Yale University$533K · 1 project
Funding institutes
- NCI$1.8M · 3
Activity codes funded
- R013 records
Most recent new awards
- High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics (opens NIH RePORTER)
Yale University · 1R01CA315012-01 · NCI · Notice Sep 16, 2026
$533KR01
- Clinical Translation of MR Cytometry (opens NIH RePORTER)
Vanderbilt University Medical Center · 1R01CA308592-01A1 · NCI · Notice Jul 15, 2026
$695KR01
What its predecessor PAR-23-259 funded
PAR-25-079 reissues PAR-23-259. Its funding history is the best guide to who wins under this program: 1 project and $528K in FY2022–FY2026.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$528K
Award dollars under PAR-23-259, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 1 | 1 | $528K |
Institutions with the most funding
- Molecular Theranostics, LLC$528K · 1 project
Funding institutes
- NCI$528K · 1
Activity codes funded
- R011 record
Most recent new awards
- Development of next-generation targeted MRI contrast agents (opens NIH RePORTER)
Molecular Theranostics, LLC · 1R01CA297667-01A1 · NCI · Notice Aug 20, 2026
$528KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-079. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budget is limited to less than 500,000 direct cost per year and must reflect the actual needs of the proposed project.
- Project period
- The maximum project period is 5 years.   NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-23-259.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.